Trellis Bioscience: Series CDeveloping native human monoclonal antibodies to treat intractable infectious diseasesOct 4, 2026RoundOSTrellis BioscienceCompany profile and funding historySourcesprnewswire.comMore in BiotechAusperBio · Series CProFound Therapeutics · StrategicTransfyr · SeedBiotechUnited StatesNorth AmericaSeries C+